Oncozenge AB (ONCOZ) - Total Liabilities
Based on the latest financial reports, Oncozenge AB (ONCOZ) has total liabilities worth Skr15.92 Million SEK (≈ $1.71 Million USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore ONCOZ net asset momentum to track the company's year-over-year net asset growth rate.
Oncozenge AB - Total Liabilities Trend (2020–2025)
This chart illustrates how Oncozenge AB's total liabilities have evolved over time, based on quarterly financial data. See ONCOZ free cash flow generation to measure how efficiently the company converts operating cash flow to free cash.
Oncozenge AB Competitors by Total Liabilities
The table below lists competitors of Oncozenge AB ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
NEWMARK SECURITY LS-005
F:NN10
|
Germany | €7.72 Million |
|
RLF Agtech Ltd
AU:RLF
|
Australia | AU$18.82 Million |
|
Pan Entertainment Co. Ltd
KQ:068050
|
Korea | ₩56.31 Billion |
|
Redivium Ltd
AU:RIL
|
Australia | AU$720.06K |
|
Sadbhav Infrastructure Project Limited
NSE:SADBHIN
|
India | Rs56.20 Billion |
|
Barramundi Group Ltd
OL:BARRA
|
Norway | Nkr24.80 Million |
|
CPL Group Public Company Limited
BK:CPL
|
Thailand | ฿1.39 Billion |
|
Leslies Inc
NASDAQ:LESL
|
USA | $1.14 Billion |
Liability Composition Analysis (2020–2025)
This chart breaks down Oncozenge AB's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Oncozenge AB market capitalisation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.01 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -27.13 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 1.04 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Oncozenge AB's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Oncozenge AB (2020–2025)
The table below shows the annual total liabilities of Oncozenge AB from 2020 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | Skr15.92 Million ≈ $1.71 Million |
+973.05% |
| 2024-12-31 | Skr1.48 Million ≈ $159.70K |
-12.65% |
| 2023-12-31 | Skr1.70 Million ≈ $182.84K |
-41.82% |
| 2022-12-31 | Skr2.92 Million ≈ $314.24K |
-40.46% |
| 2021-12-31 | Skr4.90 Million ≈ $527.75K |
-45.60% |
| 2020-12-31 | Skr9.01 Million ≈ $970.05K |
-- |
About Oncozenge AB
OncoZenge AB (publ), a pharmaceutical company, engages in the development of treatment for pain relief in patients suffering from oral pain caused by radiation therapy and chemotherapy for cancer in Sweden. It offers BupiZenge, which is in Phase 3 clinical trials for the treatment of pain in the oral cavity. The company was incorporated in 2020 and is headquartered in Bromma, Sweden.